Drug Profile
Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company
Alternative Names: BI-10773; Jardiance; OboravoLatest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Duke Clinical Research Institute; Eli Lilly and Company; Kobe University; Medical University of Vienna; Mount Sinai Hospital (Toronto); University of Oxford; Yale University
- Class Antihyperglycaemics; Benzhydryl compounds; Cardiovascular therapies; Chlorinated hydrocarbons; Cyclic ethers; Glucosides; Heart failure therapies; Small molecules; Urologics
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cardiovascular disorders; Chronic heart failure; Renal failure; Type 2 diabetes mellitus
- Phase III Acute heart failure; Gestational diabetes; Heart failure; Insulin resistance; Type 1 diabetes mellitus
- Phase II Decompensated heart failure; Kidney disorders
Most Recent Events
- 06 Apr 2024 Adverse events and efficacy data from the phase-III EMPACT-MI trial in Acute heart failure released by Eli Lilly and Company
- 23 Jan 2024 Registered for Renal failure in Canada (PO)
- 05 Nov 2023 Boehringer Ingelheim completes a phase III EMPACT-MI trial in Acute heart failure in USA, Ukraine, Spain, Serbia, Russia, Romania, Poland, Netherlands, South Korea, Japan, Israel, India, Hungary, Germany, France, Denmark, China, Canada, Bulgaria, Brazil, Australia, Argentina (PO) (NCT04509674)